Humacyte (HUMA) Capital Expenditures (2020 - 2026)

Humacyte (HUMA) has 7 years of Capital Expenditures data on file, last reported at $175000.0 in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $175000.0, down 23.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $831000.0 (down 41.02% YoY), and the FY2025 annual result was $884000.0, down 43.77% from the prior year.
• Capital Expenditures climbed to $175000.0 in Q1 2026 per HUMA's latest filing, from $39000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.2 million in Q1 2023 and troughed at -$1.8 million in Q4 2023.
• A 5-year average of $179411.8 and a median of $175000.0 in 2026 frame the typical range for Capital Expenditures.
• On a YoY basis, Capital Expenditures climbed as much as 3740.0% in 2023 and fell as far as 2830.16% in 2023.
• A 5-year view of Capital Expenditures shows it stood at -$63000.0 in 2022, then sank by 2830.16% to -$1.8 million in 2023, then jumped by 103.41% to $63000.0 in 2024, then slumped by 38.1% to $39000.0 in 2025, then jumped by 348.72% to $175000.0 in 2026.
• Business Quant data shows HUMA's Capital Expenditures at $175000.0 in Q1 2026, $39000.0 in Q4 2025, and $49000.0 in Q3 2025.